EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma

Journal of Clinical Pathology

Volumn 66, Issue 9, 2013, Pages 744-748

  Cooper, W A ^a,b   Yu, B ^a,c   Yip, P Y ^a,c,d   Ng, C C ^a   Lum, T ^a   Farzin, M ^e   Trent, R J ^a,c   Mercorella, B ^a   Clarkson, A ^e   Kohonen Corish, M R J ^b,d,f   Horvath, L G ^a,c,d   Kench, J G ^a,c,d   McCaughan, B ^a,c   Gill, A J ^c,e   O'Toole, S A ^a,c,d  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN SYDNEY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e ROYAL NORTH SHORE HOSPITAL   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ANTIBODY SPECIFICITY; ARTICLE; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DNA EXTRACTION; EXON; FALSE POSITIVE RESULT; FEMALE; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PATHOGENESIS; POINT MUTATION; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG; LUNG NEOPLASMS; MALE; MASS SPECTROMETRY; MIDDLE AGED; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SENSITIVITY AND SPECIFICITY; TISSUE ARRAY ANALYSIS;

EID: 84882831490     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2013-201607     Document Type: Article

References (22)

1. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46.
2. Yip P, Yu B, Cooper W, et al. Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma. J Thorac Oncol 2013;8:408-14.
3. Travis WD, Brambilla E, Muller-Hermelink HK, et al. eds. World Health Organisation classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press, 2004.
4. Cooper W, Kohonen-Corish M, Chan C, et al. Prognostic significance of DNA repair proteins MLH1, MSH2 and MGMT expression in non-small cell lung cancer and precursor lesions. Histopathology 2008;52:613-22.
5. Selinger C, Cooper W, Al-Sohaily S, et al. Loss of special AT-rich binding protein 1 expression is a marker of poor survial in lung cancer. J Thorac Oncol 2011;6:1-11.
6. Li G, Luo X, He Jea. A novel liquidchip platform for simultaneous detection of 70 alleles of DNA somatic mutations on EGFR, KRAS, BRAF and PIK3CA from formalin-fixed and paraffin-embedded slides containing tumor tissue. Clin Chem Lab Med 2011;49:191-5.
7. Le H, Fung D, Yu B, et al. Capillary electrophoresis: new technology for DNA diagnostics. Pathology 1998;30:304-8.
8. Ilie M, Hofman V, Bonnetaud C, et al. Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma. Virchows Arch 2010;457:483-95.
9. Kitamura A, Hosoda W, Sasaki E, et al. Immunohistochemical detection of EGFR mutation using mutation-specific antibodies to lung cancer. Clin Cancer Res 2010;16:3349-55.
10. Yu J, Kane S, Wu J, et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 2009;15:3023-8.
11. Angulo B, Conde E, Suarez-Gauthier A, et al. A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry. PLoS One 2012;7:e43842.
12. Brevet M, Arcila M, Ladanyi M. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn 2010;12:169-76.
13. Kato Y, Peled N, Wynes M, et al. Novel EGFR mutation specific antibodies for NSCLC: Immunohistochemistry as a possible screening method for EGFR mutations. J Thorac Oncol 2010;5:1551-8.
14. Kawahara A, Azuma K, Sumi A, et al. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry. Lung Cancer 2011;74:35-40.
15. Kawahara A, Yamamoto C, Nakashima K, et al. Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis. Clin Cancer Res 2010;16:3163-70.
16. Simonetti S, Molina M, Queralt C, et al. Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small cell carcinoma. J Transl Med 2010;8:135.
17. Wu S, Chang Y, Lin J, et al. Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction. PLoS One 2011;6:e23303.
18. Kozu Y, Tsuta K, Kohno T, et al. The usefulness of muation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinom. Lung Cancer 2011;73:45-50.
19. Hasanovic A, Ang D, Moreira A, et al. Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma. Lung Cancer 2012;77:299-305.
20. Cheng L, Alexander R, Maclennan G, et al. Molecular pathology of lung cancer: key to personalized medicine. Modern Pathology 2012;25:347-69.
21. Dimou A, Agarwal S, Anagnostou V, et al. Standardization of epidermal growth factor receptor (EGFR) measurement by quantitative immunofluorescence and impact on antibody-based mutation detection in non-small cell lung cancer. Am J Pathol 2011;179:580-9.
22. Yasuda H, Kobayashi S, Costa D. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Oncology 2012;13:e23-31.